The newer meta-analyses did not add significantly to the views expressed in the previous Type 2 diabetes guideline. The findings of the ROSSO study44 and the data from the large Kaiser Permanente cohorts43 added considerable confidence to the view that SMBG was an integral part of effective patient education packages and enabled the effective use of many other therapies and lifestyle interventions. The view in the previous guideline that self-monitoring of plasma glucose is not a stand-alone intervention was endorsed
